SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla’s arm recalls 7992 bottles of Difluprednate Ophthalmic Emulsion in US market

22 Aug 2022 Evaluate

Cipla’s New Jersey-based unit -- Cipla USA, Inc is recalling 7,992 bottles of Difluprednate Ophthalmic Emulsion, used to treat swelling and pain after eye surgery, in the US market. The recalling of the lot is due to ‘lack of assurance of sterility’. There were complaints regarding ''defective container closure’. The affected lot was manufactured in India and marketed in the US by Cipla USA, Inc.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1237.70 -0.60 (-0.05%)
20-Apr-2026 10:50 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1236.30
Cipla 1237.70
Zydus Lifesciences 943.20
Lupin 2331.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×